Seven Grand Managers LLC Acquires Shares of 75,000 Evommune, Inc. $EVMN

Seven Grand Managers LLC acquired a new stake in Evommune, Inc. (NYSE:EVMN) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $1,284,000. Seven Grand Managers LLC owned 0.24% of Evommune as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new position in Evommune in the 4th quarter valued at approximately $34,000. Capricorn Fund Managers Ltd acquired a new position in Evommune in the 4th quarter valued at approximately $1,027,000. Geode Capital Management LLC bought a new stake in Evommune in the fourth quarter worth approximately $1,881,000. Finally, Sectoral Asset Management Inc. bought a new stake in Evommune in the fourth quarter worth approximately $10,084,000.

Evommune Stock Up 0.2%

NYSE:EVMN opened at $23.39 on Thursday. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20. The firm has a fifty day moving average price of $24.20. The firm has a market cap of $842.62 million and a price-to-earnings ratio of -2.46.

Evommune (NYSE:EVMN) last posted its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. Equities analysts anticipate that Evommune, Inc. will post -2.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Morgan Stanley boosted their target price on shares of Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings assumed coverage on shares of Evommune in a research report on Tuesday, February 3rd. They issued a “sell (e)” rating for the company. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Evommune in a research report on Tuesday. Evercore reissued an “outperform” rating and issued a $55.00 target price on shares of Evommune in a research report on Tuesday, February 10th. Finally, Clear Str raised shares of Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Evommune has an average rating of “Buy” and an average target price of $49.25.

Evommune Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.